Werewolf Therapeutics, Inc. (HOWL)

Market Cap	45.87M -23.4%
Revenue (ttm)	21.00M
Net Income	-34.61M
EPS	-0.75
Shares Out	48.60M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,330,506
Open	0.9700
Previous Close	0.9983
Day's Range	0.9333 - 1.0200
52-Week Range	0.2700 - 2.3800
Beta	0.29
Analysts	n/a
Price Target	n/a
Earnings Date	Jul 31, 2026

About HOWL

Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatm...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 30, 2021
• Employees: 14
• Stock Exchange: NASDAQ
• Ticker Symbol: HOWL
• Website: https://werewolftx.com

Financial Performance

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Sep 3, 2026

Data Sources Report a data error